R21

R21
Name	R21
Type	recombinant protein vaccine
Target	Plasmodium falciparum
Developer	University of Oxford, MRC Unit The Gambia, Serum Institute of India
Route	intramuscular
Components	circumsporozoite protein nanoparticle, adjuvant

R21 R21 is a recombinant protein nanoparticle malaria vaccine candidate targeting Plasmodium falciparum circumsporozoite antigen. It was developed through collaborations involving the University of Oxford, the MRC Unit The Gambia, and the Serum Institute of India, and has been evaluated in clinical trials in Burkina Faso, Mali, Ghana, and UK settings. The vaccine uses a hepatitis B surface antigen scaffold and an adjuvant formulation to elicit antibody responses intended to reduce clinical episodes of malaria and severe disease in children.

Overview

R21 is based on a chimeric particle combining fragments of circumsporozoite protein from Plasmodium falciparum displayed on a hepatitis B surface antigen-like scaffold previously exploited in vaccines like those for hepatitis B. The formulation pairs the antigen with a licensed adjuvant platform to enhance humoral immunity, similar in intent to approaches used by GlaxoSmithKline for the RTS,S/AS01 vaccine. Trials have compared R21 to existing malaria control measures promoted by organizations such as the World Health Organization, the Bill & Melinda Gates Foundation, and national public health bodies in endemic countries. Collaborators have included investigators from Liverpool School of Tropical Medicine, Imperial College London, Karolinska Institutet, and research institutes across Africa and Asia.

History and Development

Conceptual work on nanoparticle presentation of circumsporozoite antigen drew on research from groups at the University of Oxford and earlier vaccine platforms developed with support from the Wellcome Trust and the UK Department for International Development (DFID). Field efficacy trials were planned and executed with partnerships involving the MRC Unit The Gambia, the University of Oxford Clinical Trials Unit, and national ministries of health in Burkina Faso, Mali, and Ghana. Manufacturing scale-up involved technology transfer to the Serum Institute of India and coordination with regulators including the European Medicines Agency and national regulatory authorities in participating African states. Funding and policy dialogue included contributions from PATH, the Gates Foundation, and advisory input from the WHO SAGE.

Composition and Mechanism of Action

The antigenic core incorporates repeats from the circumsporozoite protein of Plasmodium falciparum arrayed on a hepatitis B surface antigen-like particle; this mirrors design principles used in licensed vaccines for hepatitis B and experimental nanoparticle vaccines pursued at institutions such as Harvard Medical School and Massachusetts Institute of Technology. The adjuvant employed in several formulations has related chemistry to oil-in-water and saponin-containing adjuvants used by manufacturers like GSK and Novavax, with mechanistic goals similar to those targeted in studies at the National Institutes of Health. Immunological endpoints measured in trials included anti-circumsporozoite IgG titers, opsonophagocytic activity, and cellular responses analogous to assays conducted at the Institut Pasteur, Walter Reed Army Institute of Research, and university immunology centers like Johns Hopkins University.

Clinical Trials and Efficacy

Phase IIb and Phase III trials were conducted in seasonal transmission settings in Burkina Faso and Mali and in controlled human malaria infection studies in the UK. Trial design and analysis involved collaborations with entities including the London School of Hygiene & Tropical Medicine, Imperial College London, and national ethics committees. Reported efficacy figures in some seasonal trial cohorts approached or exceeded results reported for the RTS,S trial outcomes previously published by consortia including GSK and African research networks; comparisons referenced standards set by bodies such as the WHO and peer-reviewed journals like The Lancet and The New England Journal of Medicine. Additional studies evaluated coadministration with routine immunizations endorsed by the UNICEF and national Expanded Programme on Immunization schedules.

Safety and Side Effects

Safety assessments followed protocols endorsed by the ICH and national regulatory authorities, with monitoring for solicited local reactions, systemic events, and serious adverse events as per standards used in vaccine trials at the US Food and Drug Administration and European Medicines Agency. Reported adverse events included transient injection site pain and fever, similar to reactogenicity profiles described for licensed vaccines from manufacturers like Pfizer–BioNTech and Moderna in separate contexts. Data safety monitoring boards convened with representation from institutions such as WHO and independent academic centers to adjudicate safety signals.

Regulatory Status and Deployment

Regulatory review involved submissions to national authorities in trial countries and engagement with multilateral agencies, with manufacturing scale-up agreements implemented with the Serum Institute of India to enable broader production. Policy recommendations and potential inclusion in immunization programs would follow assessments by the World Health Organization and national immunization technical advisory groups in Ghana, Burkina Faso, and Mali. Deployment planning has included considerations similar to rollout strategies used for other large-scale vaccines coordinated by Gavi, the Vaccine Alliance and supply-chain arrangements informed by logistics research at organizations such as UNICEF and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Category:Malaria vaccines Category:Vaccines developed in the United Kingdom